Last reviewed · How we verify
ANAVEX3-71 oral capsules
ANAVEX3-71 is a sigma-1 receptor agonist that modulates neuroprotective and neuroinflammatory pathways in the central nervous system.
ANAVEX3-71 is a sigma-1 receptor agonist that modulates neuroprotective and neuroinflammatory pathways in the central nervous system. Used for Alzheimer's disease, Parkinson's disease.
At a glance
| Generic name | ANAVEX3-71 oral capsules |
|---|---|
| Sponsor | Anavex Life Sciences Corp. |
| Drug class | Sigma-1 receptor agonist |
| Target | Sigma-1 receptor (σ1R) |
| Modality | Small molecule |
| Therapeutic area | Neurology |
| Phase | Phase 2 |
Mechanism of action
The drug activates sigma-1 receptors, which are involved in cellular stress response, mitochondrial function, and neuroinflammation. By engaging this target, ANAVEX3-71 is designed to provide neuroprotection and reduce neurodegeneration in neurodegenerative diseases. This mechanism is part of Anavex's broader platform targeting sigma-1 and muscarinic receptors for CNS disorders.
Approved indications
- Alzheimer's disease
- Parkinson's disease
Common side effects
- Headache
- Nausea
- Dizziness
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |